Brand Leading Inheritance and Innovation | Mengyang Pharmaceutical Becoming a New Member of the "Traditional Chinese Medicine Brand Cluster"
On December 9-10, 2023, the 2023 China Traditional Chinese Medicine Industry High Quality Development Confere...
Meet Guangzhou Pharmaceutical "Flash" Guangzhou - Mengyang Pharmaceutical Exhibits at the 87th National Drug Fair
Accompanied by tranquility and warmth, December winter has quietly arrived. On this occasion, the Drug Fair has als...
Good news: Mengyang Pharmaceutical has been awarded the title of "National Green Factory"
Recently, the Ministry of Industry and Information Technology of China released the list of green manufacturing co...
Good news: Mengyang Pharmaceutical has completed Series B of RMB 100 million financing | Langzi Hanya Leading Investment
Recently, the company completed a Series B financing of 100 million yuan, led by Langzi Hanya, Jinggangshan Zhend...
Zhou Jinzheng, Secretary of the Ningshan County Party Committee in Shaanxi Province, and his delegation visited Mengyang Pharmaceutical for research and inspection
On November 8, 2023, Zhou Jinzheng, Secretary of the Ningshan County Committee of Shaanxi Province, Zhang Yi...
"Shengbai Oral Liquid" has been granted PCT international patent authorization
Recently, the PCT international patent for Shengbai Oral Liquid (also known as "Drug For Treating Leukop...
Mengyang Pharmaceutical was awarded the "2023 Best Practice Case of Traditional Chinese Medicine Inheritance and Innovation 50"
The 15th China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference, hosted by the China Pharmace...
Mengyang Pharmaceutical's Class I New Drug DH001 was invited to give a presentation at the 16th Shanghai International Conference on Traditional Chinese Medicine and Natural Medicines (STCM 2023)
From October 24 to 26, 2023, sponsored by Shanghai Biomedical Science and Technology Development Center, Shangh...
New members added to the clinical evidence-based study of Mengyang brand polyporus polysaccharide capsules -2022 edition "Interpretation of Clinical Pathway Therapy Drugs"
The exclusive medical insurance product of Hubei Mengyang Pharmaceutical Co., Ltd. - Polyporus umbellatus polysac...
Xiong Xiangtao, Secretary of the Party Group and Director of the Provincial Drug Administration, and his delegation conducted research on Mengyang Pharmaceutical
On the afternoon of September 20, 2023, Xiong Xiangtao, Secretary of the Party Group and Director of the Provin...
Mengyang Pharmaceutical announces the completion of Phase II clinical trial for Class 1 new drug DH001, with the first subject administration completed
Mengyang Pharmaceutical is a modern joint-stock pharmaceutical high-tech enterprise, mainly engaged in the research an...
Good news! Mengyang Pharmaceutical has been shortlisted for green manufacturing in Hubei Province
Recently, the Department of Economy and Information Technology of Hubei Province announced the list of green manu...
Our traditional Chinese medicine company cooperates with mainstream medical institutions in the United States
Transferred from: Xinhua Finance and EconomicsAt the 2023 Beijing Service Trade Fair Beijing Traditional Chi...
Innovation in the Mode of Traditional Chinese Medicine Going Abroad: Mengyang Pharmaceutical breaks the deadlock first
On September 2nd, 2023, the China International Trade in Services Fair officially opened in Beijing.At the trad...
Good news! Zhang Min, Chairman of Mengyang Pharmaceutical, elected as Executive Member of the 8th Traditional Chinese Medicine Professional Committee of the China Association of Integrated Traditional Chinese and Western Medicine
On August 17-19, 2023, the 8th Academic Annual Meeting of the Professional Committee of Traditional Chinese Me...
Recruitment notice for volunteers in clinical research of Zhuling polysaccharide capsules
Dear friendHello!The randomized, double-blind, loaded, placebo-controlled, multicenter clinical study on the efficacy...
Announcement of Mengyang Pharmaceutical's Participation | The 8th Academic Annual Meeting of the Chinese Association of Traditional Chinese Medicine Professional Committee in 2023 and the 12th Academic Annual Meeting of the Chinese Medicine Analysis Profe
The groundbreaking ceremony for the construction of the headquarters and innovative drug research and development production base of Mengyang Pharmaceutical Group has been successfully completed
On the morning of July 3, 2023, the headquarters and innovative drug research and development production base construc...
"Brand Leading, Inheritance and Innovation" Member Unit Theme Screening: Hubei Mengyang Pharmaceutical Co., Ltd
The Clinical Application Practice Forum of Integrating True Knowledge and Shengbai Oral Liquid (Mixture) was successfully held
Sun, moon, stars, and rivers, with friendly lights, summer rain and winter snow, coexisting in the north and south. On...
Expert Consensus Tour of Shengbai Oral Liquid (Mixture) Successfully Held at Shanghai Station
On November 20, 2022, the "Expert Consensus Tour on the Diagnosis and Treatment of Bone Marrow Inhibition...
Good news: Mengyang Pharmaceutical has been awarded the title of "2022 Hubei Province Manufacturing Single Champion Enterprise"
Recently, the Hubei Provincial Department of Economy and Information Technology publicly announced the list of 20...
New members added to the clinical evidence-based treatment of Mengyang brand Shengbai oral liquid (mixture) -2022 edition "Interpretation of Clinical Pathway Therapy Drugs"
Hubei Mengyang Pharmaceutical Co., Ltd.'s exclusive medical insurance product - Shengbai Oral Liquid (mixtur...
Shengbai Oral Liquid Bone Marrow Inhibition Summit Forum • Zhengzhou Station Salon held
On October 21, 2022, in this deep autumn season with abundant autumn and falling leaves. The "Shengbai Oral L...
Warm congratulations to Mengyang Pharmaceutical for winning a series of honors such as "National Intellectual Property Advantage Enterprise" and "Hubei Provincial Enterprise Technology Center"
2022 will be a difficult and rewarding year for Mengyang Pharmaceutical. In the first half of the year, due to the im...
Shengsheng Continues to Rise • Gathering Emotions in Qilu | Record of the Successful Holding of the "Shengbai Oral Liquid Bone Marrow Inhibition Summit Forum • Shandong Station"
On September 13, 2022, the "Shengbai Oral Liquid Bone Marrow Inhibition Summit Forum • Shandong Statio...
Academic promotion silhouette of Mengyang Pharmaceutical's market
On August 11, 2022, the Summit Forum on Bone Marrow Inhibition of Shengbai Oral Liquid (Mixture)& Nbsp; ...
Warm congratulations to Mengyang Pharmaceutical on the successful convening of the 2022 Marketing Center Semiannual Meeting
In July, fireworks slowly arrive, and half of the year has passed. From July 23rd to 25th, 2022, the marketing cente...
Good news: Mengyang Pharmaceutical has been selected as a reserve "Golden Seed" enterprise for listing in Hubei Province
Recently, the press conference for the 2022-2023 listing reserve "Golden Seed" enterprises in Hubei Provi...
Warmly congratulate Mengyang Pharmaceutical on the successful convening of the "Cloud Forum on New Ideas for Diagnosis and Treatment of Myelosuppression".
In this warm season, we ushered in the fiery May. On May 28, 2022, the "Cloud Forum on New Ideas for Diagn...
Mengyang Pharmaceutical Co., Ltd. completed Series A financing to accelerate the development of new drugs in the field of cancer treatment-related diseases
(Left: Zhang Min, Chairman of Mengyang Pharmaceutical, Right: Yang Weidong, Chairman of Jifan Capital.)Rece...
Congratulations to Mengyang Pharmaceutical for being awarded the honorary title of "Tax Contribution Enterprise".
In order to commend the advanced, establish a model, give full play to the leading and exemplary role of outstanding en...
Mengyang Pharmaceutical announced the results of the Phase I registration clinical trial of DH001, the world's first oral cardioprotective agent (reducing doxorubicin cardiotoxicity), in China
On January 21, 2022, Mengyang Pharmaceutical announced that its self-developed small molecule chemical drug Class 1...
Congratulations to Mengyang Pharmaceutical for being named "Invisible Champion Science and Technology Little Giant Enterprise"
Congratulations to Mengyang Pharmaceutical for being named "Invisible Champion Science and Technology Littl...
Good news! Mengyang brand Shengbai Oral Liquid (Mixture) was listed in the "2021 Clinical Value Chinese Patent Medicine Brand List"
On December 18, the "2021 Annual Industry Information Conference of the China Association of Traditional C...
Congratulations on the successful convening of the RCT research project after the launch of the polysaccharide capsules
On the evening of December 3, 2021, the "Kick-off Meeting of the Clinical Research Project of Polysaccharid...
Warmly congratulate Shengbai Mixture for being included in the "Expert Consensus on the Diagnosis and Treatment of Bone Marrow Suppression Caused by Antineoplastic Drugs in the Combination of Traditional Chinese and Western Medicine"
The Expert Consensus on the Diagnosis and Treatment of Bone Marrow Suppression Caused by Antineoplastic Drugs...
Fang Hongwei, member of the Standing Committee of the Shaanxi Provincial Party Committee and Secretary-General of the Provincial Party Committee, and his party came to Mengyang, Ningshan for investigation
At 13 o'clock on June 9, 2021, Fang Hongwei, member of the Standing Committee of the Shaanxi Provincial Par...
Wang Qiyang, secretary of the Jingmen Municipal Party Committee, led a team to investigate Mengyang Pharmaceutical
In order to further clarify the goals, strengthen measures, consolidate responsibilities, accelerate the construction o...
Shengbai Oral Liquid was approved for registration as a natural medicine in Canada
Since the 18th National Congress of the Communist Party of China, the development of traditional Chinese medicine...
Congratulations to Chairman Zhang Min for being elected as a member of the 7th Council of the China Association of Traditional Chinese Medicine
On December 5, the 7th National Congress of the 7th China Association of Traditional Chinese Medicine was held ...
Good news! Mengyang's "Shengbai Oral Liquid (Mixture)" was selected into the 2020 Hubei Province Innovative Product Application Demonstration Recommended Catalog
Recently, the Hubei Provincial Department of Economy and Information Technology announced the "2020 Hubei P...
Good news! Mengyang Pharmaceutical, as a leading enterprise, participated in poverty alleviation and helped Ningshan to be shortlisted as a typical case of "National Consumption Poverty Alleviation".
From September 16 to 17, 2020, the "2020 National Consumption Poverty Alleviation Forum" was held in Y...
Good news丨Mengyang Pharmaceutical was listed as a key project of the national "Science and Technology to Help the Economy 2020".
A few days ago, the Provincial Department of Science and Technology announced the national "Science and Tech...
The first phase of the application of raw white oral liquid in the United States for dietary supplements successfully passed the FDA review
In order to actively respond to the above-mentioned "One Belt, One Road" development strategy and make p...
Liu Wenbin, deputy director of the Provincial Food and Drug Administration, visited Mengyang Pharmaceutical Jingmen Base
In order to thoroughly implement the spirit of General Secretary Xi Jinping's important speech on the overall p...
Welcome to the 10th anniversary of Mengyang | A class of new drugs has been approved for clinical use
A class of new drugs has been approved for clinical use On January 18, 2020, the company ushered in major good news -...
A prescription gives birth to 100 million yuan enterprises (Hubei Daily)
Hubei Daily News (reporter Yan Yuntao, correspondent Gao Xianyong) "In 2019, the company achieved sales rev...
